... immuneresponses in humans. Further improvements of the recombinants, using the E6 and E7 transgenes deleted of the p53 and p105Rb cellular binding domain, might fur-ther increase the safety of the vaccine. ... non-specificimmune stimulation by the doubling of the amount of the FP vector used in Protocol 3. However, when plates werecoated with CaSki lysates instead of the E6 or E7 proteins the antibody titre was ... protocols were applied. In Protocol 1, the animals were immunised with the FPE6 recombinant (108 PFU/animal), in Proto-col 2 with the FPE7 recombinant (108 PFU/animal), in Protocol 3 with...